$DMRA
Damora Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
DMRA chart
What traders are saying about $DMRA
Latest postsDamora Therapeutics, Inc. news
- Damora Therapeutics at Guggenheim conference: cash, pipeline drive By Investing.com
Investing.com Canada ·
- Damora Therapeutics Stock In Focus After Wider Quarterly Loss
Simply Wall St ·
- Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $51
Moomoo ·
- Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors?
Yahoo Finance ·
- Damora Therapeutics (DMRA) Starts DMR 001 Trial As Valuation Questions Grow
Simply Wall St ·
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Damora Therapeutics, Inc. (DMRA) Tops Q3 EPS by 8c
StreetInsider ·
- How Is Damora Therapeutics(NASDAQ:DMRA) Advancing Its CLARITY-101 Trial for Blood Disorders in Q3 2026?
Kalkine ·
- Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Yahoo Finance ·
- Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
Yahoo Finance ·
- Lab tests put Damora’s experimental therapy at 95 times the potency of a reference antibody, on average.
Stock Titan ·
- Damora Therapeutics reveals promising preclinic...
Pluang ·
Damora Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M |
| Diluted EPS | $3.98 | $-18.53 | $-36.08 | $-2.43 |
| Total assets (year end) | $260.5M | $17.1M | $38.2M | $73.2M |
| Cash and equivalents (year end) | $257.6M | $14.2M | $21.5M | $32.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Damora Therapeutics, Inc.
- Ticker
- DMRA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1800315
- Former names
- Galecto, Inc., Galecto Inc.
Frequently asked questions
What exchange is Damora Therapeutics, Inc. listed on?
Damora Therapeutics, Inc. trades on the Nasdaq under the ticker symbol DMRA.
What industry is Damora Therapeutics, Inc. in?
Damora Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Damora Therapeutics, Inc. headquartered?
Damora Therapeutics, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Damora Therapeutics, Inc.'s fiscal year end?
Damora Therapeutics, Inc.'s fiscal year ends on December 31.